



Ophthotech Corp.
Investor Relations Department
Five Vaughn Drive
Suite 106
Princeton, NJ 08540
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: OPHT ¹

| | |
|-------------------|----------------------------|
| Last Trade: | 2.47 |
| Trade Time: | 4:00 PM ET Oct 18, 2017 |
| Change: | -0.02 (0.803%) |
| Day Range | 2.42 - 2.52 |
| 52-Week Range | 2.24 - 40.34 |
| Volume | 249,329 |
| Market Cap. (\$M) | 88.772 |
| Shares Out (M) | 35.940 |


¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

... [\(more\)](#)

Stock Performance



Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Apr 24, 2017

[Definitive Proxy Statement](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)